Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NVP-2002
- Development stage
- Phase 4
- Lead developer
- Navipharm
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**NVP-2002** is an oral fixed-dose antidiabetic combination product developed by NVP Healthcare that contains **linagliptin** and **metformin**. Linagliptin inhibits dipeptidyl peptidase-4, prolonging endogenous incretin activity and supporting glucose-dependent insulin secretion, while metformin primarily lowers hepatic glucose production and improves insulin sensitivity. NVP-2002 was evaluated in a completed Phase 1 pharmacokinetic and safety study in healthy adults against co-administration of its individual component products, NVP-2002-R1 and NVP-2002-R2.
- Brand names
- SynjardySynjardy XR
- Other names
- NVP-2002-R1/NVP-2002-R2NVP-2002-R2/NVP-2002-R1
02
Targets
ND1 (Mitochondrial electron transport chain complex I)SGLT2 (Sodium-glucose cotransporter protein subunit 2)
Beyond the preview
Go deeper on NVP-2002.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NVP-2002.